Havrylyuk N. Influence of complex pathogenetically based treatment on the clinical course of chronic Helicobacter-pylori-associated erosive gastritis considering liver function

Українська версія

Thesis for the degree of Candidate of Sciences (CSc)

State registration number

0411U000466

Thesis Registration Form

0411U000466.pdf

Applicant for

Specialization

  • 14.01.36 - Гастроентерологія

11-02-2011

Specialized Academic Board

Д 20.601.01

Ivano-Frankivsk national medical university

Essay

Object - 129 patients with chronic Helicobacter-pylori-associated erosive gastritis (CEG). Clinical and pathological characteristics of the CEG course and the efficiency of complex treatment depending on liver function with follow-up study have been investigated. It has been established that one of the pathogenetic factors of recurrent CEG is concomitant with chronic liver function disorders. More pronounced changes of CEG clinic-morphological pattern, Hp contamination level, ІL-1beta rate, trace elements, oxidative imbalance in case of CEG along with chronic liver function disorders have been ascertained. The differentiated treatment with gastro-norm (quadrotherapy) and citrarginine has been elaborated depending to liver function. Branch - medicine.

Read more

Files

Dis1.doc

Dis1.doc

aref.doc

Similar theses

0521U101202

Elina G. Manzhalii

Hepatic Encephalopathy: Aspects of Diagnostics, Clinical and Laboratory and Psychological Peculiarities, and Treatment Optimization

0521U100881

Katerina V. Pivtorak

Diagnosis, prognosis and pharmacological correction of endothelial dysfunction in non-alcoholic fatty liver disease (clinical and experimental study)

0420U102383

Psaryeva Inessa V.

Clinical, diagnostic and prognostic value of inflammation biomarkers in patients with ulcerative colitis

0420U102382

Stan Mychailo Petrovych Mychailo P

Peculiar features of the course of gastroesophageal reflux disease and its management in patients with carbon and lipid metabolism disorders

0420U102152

Konenko Irina S

Predictors of fibrosis progression in patients with chronic diffuse liver diseases